Acute Respiratory Distress Syndrome

What is ARDS?

ARDS is a devastating lung condition with no FDA approved treatment, 40%+ mortality rate, and a cost of $100K per patient.  

Patients hospitalized with ARDS incurred significantly higher resource utilization and costs than non-ARDS hospitalizations during and prior to the stay. The pattern persists for one year after hospital discharge.  

For example, ARDS patients had longer stays in the hospital (16.7 vs. 4.6 days) and they incurred higher costs of care than controls ($117,137 vs. $25,199; all p<0.05).  

ARDS patients who survive to discharge are more likely to be re-hospitalized (53.2% vs. 12.9%)  and during the subsequent year ARDS patients incurred higher annual total costs ($82,749 vs. $22,670; both p<0.05).  

All of this leads to unfavorable health economics for the ecosystem and prolonged suffering for the patients and their families.
Source: Healthcare costs utilization and costs of patients hospitalized with acute respiratory distress syndrome (ARDS) in US commercially-insured individuals and Medicare beneficiaries Link to source

GEn-1124 (our Lead Candidate) has Multiple Mechanisms of Action in ARDS

Our Solution

Phase 1 Study in New Zealand completed

Situation: Urgent need for ARDS treatments (including COVID ARDS)
Response: GEn1E reduced timeline by ~4 months. Started dosing subjects in first human study in Jan 2021
Study at Christchurch Clinical Studies Trust (CCST)
Principal investigator has 20 year's experience working on clinical studies with p38 kinase inhibitors
Regulatory (MEDSAFE) and Ethics (HDEC) approval received for clinical study